Phospholipase is one of a very complex group of enzymes that converts phospholipids into fatty acids and other compounds. The enzymatic reaction that phospholipases catalyze serves to define them. Phospholipase A, which has members A1 and A2, Phospholipase B, which can perform both A1 and A2 reactions, Phospholipase C, and Phospholipase D are the classes.
Fatty acids and lysophospholipids are produced when phospholipase A2 (PLA2) catalyzes the hydrolysis of the sn-2 position of glycerophospholipids. Phospholipase C (PLC) transforms inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) from phosphatidylinositol 4,5-bisphosphate (PIP2). DAG and IP3 each regulate a variety of cellular processes and serve as a starting point for the creation of additional significant signaling molecules. PLC serves as the hub of numerous significant interconnected regulatory networks. The production of the lipid second messenger phosphatidic acid (PA), which is involved in fundamental cellular processes like membrane trafficking, actin cytoskeleton remodeling, cell proliferation, and cell survival, is carried out by the crucial enzyme phospholipase D (PLD).
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V73547 | (R)-Bromoenol lactone ((R,E)-Bromoenol lactone) | 478288-90-3 | (R)-Bromoenol lactone ((R)-BEL) is an irreversible, chiral, mechanism-based inhibitor of calcium-independent phospholipase gamma (iPLA2γ). |
|
V83539 | (R)-N-(1-Hydroxypropan-2-yl)palmitamide | 142128-47-0 | |
|
V73552 | (S)-Bromoenol lactone ((S)-BEL; (S,E)-Bromoenol lactone) | 478288-94-7 | (S)-Bromoenol lactone ((S)-BEL) is an irreversible, chiral, mechanism-based inhibitor of calcium-independent phospholipase A2β (iPLA2β) in rat aortic smooth muscle (A10) cells Vasopressin-induced release of arachidonic acid with IC50 of 2 µM. |
|
V73548 | (Z)-Oleyloxyethyl phosphorylcholine | 84601-19-4 | (Z)-Oleyloxyethyl phosphorylcholine ((Z)-OPC) is an isomer of Oleyloxyethyl phosphorylcholine (OPC). |
|
V80027 | A3373 | A3373 is a new chemical phospholipase (Phospholipase) D1 (PLD1) and PLD2 inhibitor (antagonist) with IC50s of 325 nM and 15.15? Plays an important role in osteoclastogenesis. | |
|
V78499 | A4333 | A4333 is a biotinylated compound of A3373 that can inhibit phospholipase D1 (PLD1) but not PLD2. | |
|
V3849 | ACA | 110683-10-8 | ACA [also known as N-(p-amylcinnamoyl) Anthranilic Acid] is a broad-spectrum inhibitor ofphospholipase A2 (PLA2) and a TRP channel blocker. |
|
V73540 | ASM-IN-1 | 2913151-46-7 | ASM-IN-1 is a potent orally bioactive acid sphingomyelinase (ASM) inhibitor (antagonist) with IC50 of 1.5 µM. |
|
V5285 | BAPTA | 85233-19-8 | BAPTA is a selective calcium chelator. |
|
V6123 | BAPTA Tetrasodium | 126824-24-6 | BAPTA tetrasodium is a selective calcium chelator. |
|
V73550 | CAY10502 | 888320-29-4 | CAY10502 is a potent calcium-dependent cytosolic phospholipase A2 alpha (cPLA2α) inhibitor (antagonist) with IC50 of 4.3 nM against the isolated enzyme. |
|
V2160 | CAY10594 | 1130067-34-3 | CAY10594 is a potent phospholipase D2 (PLD2) inhibitor (in vitro IC50=140 nM, cellular IC50=110 nM). |
|
V2928 | CAY10650 | 1233706-88-1 | CAY10650 (CAY-10650) is a novel and highly potent inhibitor of cytosolic phospholipase A2α (cPLA2α) (IC50 = 12 nM) with anti-inflammatory activity. |
|
V19410 | Difluprednate | 23674-86-4 | Difluprednate (Durezol) is a corticosteroid thought to inhibit phospholipase A2 by inducing lipocortin. |
|
V73538 | DPTIP-prodrug 18 (P18) | 2881068-33-1 | DPTIP-prodrug 18 (P18) is an orally bioavailable, BBB (blood-brain barrier) permeable (penetrable) DPTIP precursor active molecule. |
|
V5047 | EA4 | 389614-94-2 | EA4, a quinone derivative, is a novel and potent a rPLA2 inhibitor that inhibits rPLA2 with a Kiof 130 µM. |
|
V73544 | Folipastatin | 139959-71-0 | Folipastatin is a potent phospholipase A2 inhibitor (antagonist) with IC50 of 39 μM. |
|
V73529 | GSK2647544 | 1380426-95-8 | GSK2647544 is an oral, selective Lp-PLA2 inhibitor. |
|
V21862 | GSK2814338 | 1420367-28-7 | GSK2814338 (GSK-2814338) is a novel and potent Lp-PLA2 (Lipoprotein-associated phospholipase A2) with the potential to be used for atherosclerosis and Alzheimer's disease. |
|
V2778 | GW4869 HCl | 6823-69-4 | GW4869 HCl (GW-4869; GW-69A;GW-554869A), the dihydrochloride salt ofGW4869, is a neutral, cell permeable and noncompetitive inhibitor of sphingomyelinase (SMase) (IC50 = 1 μM) and is most widely used pharmacological agent for blocking exosome generation. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
